Intracranial meningiomas: Diagnosis and treatment

Expert Review of Neurotherapeutics

Volumn 4, Issue 4, 2004, Pages 641-648

  Chamberlain, Marc C ^a   Blumenthal, Deborah T ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Intracranial meningioma; Treatment

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; EXELGYN; HYDROXYUREA; IFOSFAMIDE; MEGESTROL ACETATE; MIFEPRISTONE; PROLACTIN RECEPTOR; RECOMBINANT ALPHA INTERFERON; TAMOXIFEN; TEMOZOLOMIDE; VINCRISTINE;

AGED; BEAM THERAPY; BRAIN SURGERY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYBERKNIFE RADIOSURGERY; DISEASE COURSE; GAMMA KNIFE RADIOSURGERY; HIGH RISK PATIENT; HUMAN; LINEAR ACCELERATOR; MENINGIOMA; MOLECULAR GENETICS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SEX DIFFERENCE; SEX RATIO; STEREOTACTIC RADIOTHERAPY; STEREOTAXIC SURGERY; SURGICAL RISK; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; RADIOSURGERY;

EID: 3042741077     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.4.641     Document Type: Review

References (50)

1. Longstreth WT, Dennis LK, McGuire VM et al. Epidemiology of intracranial meningioma. Cancer 72, 639-648 (1993).
2. Wilson CB, Meningiomas: genetics, malignancy and the role of radiation in induction and treatment. J. Neurosurg. 81, 666-675 (1994). Excellent review of meningioma with the emphasis on surgery and radiotherapy.
3. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas; a review. J. Neuro-oncol. 29, 197-205 (1996).
4. De Monte F. Current management of meningiomas. Oncology 9 (1), 83-92 (1995). Excellent review of contemporary treatment of meningioma.
5. Sanson M, Cornu P. Biology of meningiomas. Acta Neurochir (Wien). 142, 493-505 (2000).
6. Mirimanoff RO, Dosoretz DE, Linggood RM et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J. Neurosurg. 62, 18-24 (1985).
7. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients: a multivariate analysis. Surg. Neurol. 26, 261-469 (1986).
8. Goldsmith BJ, Wata WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. J. Neurosurg. 80, 195-201 (1994).
9. Lunsford DL. Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal? J. Neurosurg. 80, 187-190 (1994).
10. Kondziolka D, Lunsford D, Coffey RJ, Flickinger JC. Stereotactic radiosurgery of meningiomas. J. Neurosurg. 74, 552-559 (1991).
11. Morita A, Coffey RJ, Foote RL, Schiff D, Gorman D. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. J. Neurosurg. 90, 42-50 (1999).
12. Lee JYK, Niranjan A, McInerney J, Kondziolka D, Flickinger J, Lundsford LD. Stereotactic radiosurgery providing long-term control of cavernous sinus meningiomas. J. Neurosurg. 97, 65-72 (2002).
13. Ojemann SG, Sneed PK, Larson DH et al. Radiosurgery for malignant meningioma: results in 22 patients. J. Neurosurg. 93(Suppl. 3), 62-67 (2000).
14. Flickinger JC, Kondziolka D et al. Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int. J. Radiation Oncology Biol. Phys. 56(3), 801-806 (2003). Contemporary review of radiosurgery for newly diagnosed meningioma.
15. McLaren F, Black P. Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can. J Neurol. Sci. 24, 302-306 (1997).
16. Kyritisis AP. Chemotherapy for meningiomas. J. Neuro-oncol. 29, 269-272 (1996).
17. Grunberg SM, Rankin C, Townsend C et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU-486). For the treatment of unresectable meningioma. Proc. Am. Soc. Clin. Oncol. 20, 56 (2001).
18. Kaba SE, DeMonte F, Bruner JM et al. The treatment of recurrent unresectable and malignant meningiomas with interferon α-2b. Neurosurgery 40, 271-275 (1997).
19. Schrell UMH, Rittig MG, Anders M et al. Hydroxyurea for the treatment of unresectable and recurrent meningiomas. J. Neurosurg. 86, 845-852 (1997).
20. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J. Neurosurg. 97, 341-346 (2002).
21. Grunberg SM, Weiss M. Lack of efficacy of megestrol acetate in the treatment of -unresectable meningioma. J Neuro-oncol. 8, 61-65 (1990).
22. Grunberg SM, Weiss MH, Spitz IM et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J. Neurosurg. 74, 861-866 (1991).
23. Wöber-Bringöl Ç, Wöber C, Marosi C, Prayer D. Interferon-α-2b for meningioma. Lancet 345, 331 (1995).
24. DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung A. The treatment of recurrent unresectable and malignant meningiomas with interferon-α-2b. J. Neurosurg. 86, 271-275 (1997).
25. Chamberlain MC. Malignant meningiomas: adjunct combined modality therapy. J. Neurosurg. 84, 733-736 (1996).
26. Ljunggren B. The case of general wood. J. Neurosurg. 56(4), 471-474 (1982).
27. Phillips LE, Koepsell TD, van Belle G et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology 58, 1849-1852 (2002).
28. Baumgartner JE, Sorenson JM. Meningioma in the pediatric population. J. Neuro-oncol. 29, 223-228 (1996).
29. Blumenthal D, Berho M, Bloomfield S, Schochet SS Jr, Kaufman HK. Childhood meningioma associated with meningioangiomatosis. J. Neurosurg. 78, 287-289 (1993).
30. Muccioli G, Ghe C, Faccani G, Lanotte M, Forni M, Ciccarelli E. Prolactin receptors in human meningiomas: characterization and biological role. J. Endocrinol. 153, 365-3731 (1997).
31. Jhawar BS, Fuchs CS, Colditz GA et al. Sex steroid hormone exposures and risk for meningioma. J. Neurosurg. 99, 848-853 (2003).
32. Jimenez-Hakim E, el-Azouzi M, Black PM. The effect of prolactin and bombesin on the growth of meningioma-derived cells in monolayer culture. J. Neuro-oncol. 16, 185-190 (1993).
33. Osborne Anne G. Meningiomas and other nonglial neoplasms. In: Diagnostic Neuroradiology. Mosby Year Book Inc. MO, USA, 14, 579-625 (1994). Excellent resource for the radiology of meningioma.
34. Gutman DH, Donahoe J, Perry A. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum. Mol. Genet. 9, 1495-1500 (2000). Overview of the molecular genetics of meningioma.
35. Antinheimo J, Sankila R, Carpen O et al. Population-based analysis of sporadic and Type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54, 71-78 (2000).
36. Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D. Radiation-induced meningioma: a descriptive study. J. Neurosurg. 97, 1078-1082 (2002).
37. King A, Gutmann DH. The question of familial meningiomas and schwannomas. Neurology 54, 4-5 (2000).
38. Ho D M-T, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94(5), 1538-1547 (2002).
39. Yamasaki F, Yoshioka, H, Hama S et al. Recurrence of meningiomas. Influence of vascular endothelial growth factor expression. Cancer 89(5), 1102-1110 (2000).
40. Cobb MA, Husain M, Andersen BJ, Al-Mefty O. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J. Neurosurg. 84, 85-90 (1996).
41. Magrassi L, De-Fraga C, Conti L et al. Expression of the JAK and STAT superfamilies in human meningiomas. J. Neurosurg. 91, 440-446 (1999).
42. Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J. Neurosurg. 83, 222-224 (1995).
43. Braunstein JB, Vick NA: Meningiomas: the decision not to operate. Neurology 48, 1459-1462 (1997). Overview on the need for surgery and the natural history of untreated meningioma.
44. Firsching RP, Fischer A, Peters R, Thun F, Klug N. Growth rate of incidental meningiomas. J. Neurosurg. 73, 545-547 (1990).
45. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 51, 1718-1720 (1998).
46. Niiro M, Yatsushiro K, Nakamura K, Yoshihiro K, Kuratsu J. Natural history of elderly patients with asymptomatic meningiomas. J. Neurol. Neurosurg. Psych. 68 (1), 25-28 (2000).
47. Goodwin JW, Crowley J, Eyre HJ et al. A Phase II evaluation of tamoxifen unresectable or refractory meningiomas: a Southwest Oncology Group Study. J. Neuro-oncol. 15, 73-77 (1993).
48. Herbert B, Stevens MA. Hydroxyurea chemotherapy for unresectable or residual meningioma. J. Neuro-oncol. 49(2), 165-170 (2000). A single institutions experience with the most effective chemotherapy reported for recurrent meningioma.
49. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 36, 365-374 (1995).
50. Chamberlain MC, Tsao-Wei D, Groshen S. Temozolomide for treatment resistant recurrent meningioma. Neurology 62(7), 1210-1212 (2004).